US R&D drugmakers back CFTERA to protect IP
Commenting on the support of the US Senate's introduction of the Customs Facilitation and Trade Enforcement Reauthorization Act of 2009 (CFTERA), the Pharmaceutical Research and Manufacturers of America (PhRMA) senior vice president Ken Johnson said: 'strong intellectual property (IP) protections play a critical role in spurring research and development of innovative medicines and American patients are the ultimate beneficiaries of new and better treatments and cures. We applaud the efforts of Senate Finance Committee Chairman Max Baucus (D-MT) and Ranking Member Charles Grassley (R-IA) to strengthen IP rights enforcement, improve trade facilitation, modernize the customs service and ensure import safety.'
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze